Mesoglycan: Clinical Evidences for Use in Vascular Diseases by Tufano, Antonella et al.
Hindawi Publishing Corporation
International Journal of Vascular Medicine
Volume 2010, Article ID 390643, 8 pages
doi:10.1155/2010/390643
Review Article
Mesoglycan:Clinical Evidencesfor Use in Vascular Diseases
AntonellaTufano,ClaudiaArturo,ErnestoCimino,Matteo Nicola DarioDiMinno,
Mirko DiCapua,AnnaMariaCerbone,andGiovanniDi Minno
Regional Reference Centre for Coagulation Disorders, Department of Clinical and Experimental Medicine,
AOU “Federico II” Naples 80131, Italy
Correspondence should be addressed to Antonella Tufano, atufano@unina.it
Received 1 March 2010; Revised 4 June 2010; Accepted 12 July 2010
Academic Editor: Alun H. Davies
Copyright © 2010 Antonella Tufano et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Vascular glycosaminoglycans (GAG) are essential components of the endothelium and vessel wall and have been shown to be
involved in several biologic functions. Mesoglycan, a natural GAG preparation, is a polysaccharide complex rich in sulphur
radicals with strong negative electric charge. It is extracted from porcine intestinal mucosa and is composed of heparan sulfate,
dermatan sulfate, electrophoretically slow-moving heparin, and variable and minimal quantities of chondroitin sulfate. Data on
antithrombotic and proﬁbrinolytic activities of the drug show that mesoglycan, although not indicated in the treatment of acute
arterial or venous thrombosis because of the low antithrombotic eﬀect, may be useful in the management of vascular diseases,
when combined with antithrombotics in the case of disease of cerebral vasculature, and with antithrombotics and vasodilator
drugs in the case of chronic peripheral arterial disease. The protective eﬀect of mesoglycan in patients with venous thrombosis
and the absence of side eﬀects, support the use of GAG in patients with chronic venous insuﬃciency and persistent venous ulcers,
in association with compression therapy (zinc bandages, multiple layer bandages, etc.), elastic compression stockings, and local
care, and in the prevention of recurrences in patients with previous DVT following the standard course of oral anticoagulation
treatment.
1.Introduction
Vascular glycosaminoglycans (GAG) are essential compo-
nents of the endothelium and vessel wall and have been
shown to be involved in several biologic functions. Mesogly-
can,anaturalGAGpreparation,isapolysaccharidecomplex,
rich in sulphur radicals with strong negative electric charge.
It is extracted from porcine intestinal mucosa and is com-
posed of heparan sulfate (typical content 52%), dermatan
sulfate (35%), electrophoretically slow-moving heparin
(8%), and variable and minimal quantities of chondroitin
sulfate (5%) [1]. Heparan and dermatan sulphate are throm-
bin inhibitors acting through complementary pathways,
antithrombin (AT), and heparin cofactor II, respectively [1].
Heparan sulphate also inhibits activated factor X (FXa).
In animal models, heparan sulfate and dermatan sul-
fate have been shown to display antithrombotic and pro-
ﬁbrinolytic properties to prevent atherosclerotic lesions and
to regulate the selective permeability at the microcirculatory
level [2–6].
Mesoglycan is reported to have several favorable actions
on the ﬁbrinolytic system, on macrorheologic and microrhe-
ologic parameters, and to restore the electronegativity of the
vascularendotheliumincaseofdamage[1,7,8].Mesoglycan
has a relevant proﬁbrinolytic activity, after oral adminis-
tration. This pharmacological activity of mesoglycan could
possibly involve the liberation of a certain amount of tissue
plasminogen activator (tPa) [1]. Moreover, in patients with
vascular atherosclerotic disease and with diabetes, mesogly-
can is responsible for an improvement in the dynamic prop-
erties of red cell membrane (increased membrane ﬂuidity)
[7]. This improvement in the erythrocyte membrane ﬂuidity
may be related to the variation in the red cell membrane
permeability and to the readjustment of the surface electric
charges, mediated by direct or indirect interactions of the
administered GAG with the erythrocyte membrane [7].2 International Journal of Vascular Medicine
Mesoglycan and another heparin-like substance, sulo-
dexide, potentiate the mitogenic activity of ﬁbroblast growth
factors (FGFs) and protect them from heat denaturation
and enzymatic degradation [9]. Mesoglycan seems eﬀective
in restoring defective ﬁbrinolysis in patients aﬀected by
cutaneous necrotizing venulitis [10], suggesting that in
inﬂammatory vasculitis, characterized by a reduced cuta-
neous ﬁbrinolysis (reduced release of tPA from the vascular
endothelium), the use of a ﬁbrinolytic agent should be
considered.
2.ClinicalStudies
2.1. Atherosclerosis and Diabetes Mellitus. The pro-ﬁbrino-
lytic activity of orally administered mesoglycan has been
e v a l u a t e di n1 8p a t i e n t sa ﬀected by impaired plasma ﬁb-
rinolytic activity [1]. The decreased ﬁbrinolytic activity in
the patients studied was due to generalized atherosclerotic
vascular disease or to diabetes mellitus. Mesoglycan was
administered by a single dose of 24, 48, or 72mg on 1 day
and by repeated doses of 48mg twice a day, for 9 consecutive
days. After the single administration, all the ﬁbrinolytic
parameters were signiﬁcantly and positively inﬂuenced by an
order of magnitude and a duration of eﬀects proportional
to the dose employed. After the repeated administration,
a constant and reproducible activation of the ﬁbrinolytic
system was observed without any interference with hemo-
coagulative parameters [1]. The results of this study showed
that mesoglycan has a relevant pro-ﬁbrinolytic activity
in man after oral administration. The authors supposed
that pharmacological activity of mesoglycan could possibly
involve the liberation of a certain amount of plasminogen
tissue activator [1].
Caimi et al. showed in 10 patients with vascular
atherosclerotic disease and in 15 patients with vascular
atherosclerotic disease and with non-insulin-dependent dia-
betes mellitus that mesoglycan, at doses of 100mg orally
twice daily for 30 days, was responsible for an improvement
in the dynamic properties of red-cell membrane (increased
membrane ﬂuidity) [7]. This improvement in the erythro-
cyte membrane ﬂuidity may be related to the variation in
the red-cell membrane permeability and to the readjustment
of the surface electric charges mediated by direct or indirect
interactions of the administered GAG with the erythrocyte
membrane [7].
2.2. Arterial Disease
2.2.1. Cerebrovascular Disease (Table 1). Based on the evi-
dence that high plasma ﬁbrinogen (FBR) levels are risk fac-
tors for ischemic stroke and myocardial infarction (MI) [11–
16], Oreﬁce et al. [12] evaluated the eﬀects of mesoglycan
on some parameters of the ﬁbrinolytic system in patients
with ischemic cerebrovascular disease of an atherosclerotic
nature and the side eﬀects of a long-term treatment with
this drug. Thirty patients who had previously had an athero-
thrombotic stroke, 15 men and 15 women, mean-aged 67
years, received mesoglycan 50mg twice daily, for 3 months,
to evaluate the eﬀect of the drug on plasma FBR levels, AT
concentration, and other coagulative parameters. Patients
had the last ischemic acute event 1–3 months before. The
coagulative parameters were evaluated at baseline 4 hours
after the morning dose of mesoglycan and after 7, 30 and
90 days of therapy. After 7 days of treatment, mesoglycan
signiﬁcantly decreased plasma FBR levels (P < .05). This
result was conﬁrmed after 30 and 90 days (P < .005,
and P < .001, resp.). No statistically changes in AT levels,
prothrombin time (PT), partial thromboplastin time (PTT),
or platelet count were observed with respect to baseline
values [12].
This drug’s eﬀect is poorly understood, it may be corre-
lated in some way to a protective action on the endothelial
cells, possibly maintaining the physiologic electronegativity
of the endothelial surface. The authors concluded that meso-
glycan is a safe and eﬀective drug for reducing plasma FBR
levels without interfering with other coagulative parameters
[12].
In a randomized controlled trial [11], patients were
randomized into 2 groups: one group (n = 28; 14 men, 14
women) receiving mesoglycan (50mg twice daily) and the
other group (n = 18; 12 men, 6 women) ticlopidine (250mg
twice daily). Criteria for patients enrollement were a baseline
FBR levels ≥ 350mg/dL and age > 4 0y e a r s .T h et i m eo f
stroke onset ranged from 2 to 3 months before patients
entered the study. After 2 months of treatment, the authors
found a statistically signiﬁcant reduction of both functional
(P = .01) and immunologic (P < .05) plasma FBR levels in
the group receiving mesoglycan; in the patients receiving
ticlopidine, these reductions were more signiﬁcant (P < .01
for both). However, the eﬀect was transient; it disappeared
15 days after the end of treatment. The study showed
that mesoglycan may be an eﬀective drugs for reducing
plasma FBR levels without interfering with other coagulative
parameters and without serious side eﬀects. The results of
this study conﬁrm the data of previous reports showing the
decrease of plasma FBR levels with some drugs (ticlopidine
and ﬁbrates) [17]. Other studies comparing mesoglican and
ticlopidine or other tienopiridines in arterial thromboses are
lacking in the literature, so these results are not adequately
conﬁrmed and validated.
Vecchio et al. evaluated the hematochemical and
hemorheologic eﬀects of mesoglycan, administered by the
intramuscular route to patients with a recent episode of
cerebral ischemia [13]. A total of twenty patients (13 males
and 7 females), between the ages of 45 and 75, under
observation for a cerebral ischemic episode occurring at least
2 months prior to enrollement were treated with intramus-
cular mesoglycan (30mg, twice daily) for 15 days. Blood
samples were taken prior to and at the end of treatment to
measure the investigated parameters. Following mesoglycan
treatment, the authors observed a statistically signiﬁcant
decrease in FBR plasma concentration, total cholesterol and
triglycerides, while HDL cholesterol was found to increase.
In addition, erythrocytes ﬁlterability improved at the end
of treatment. No changes were observed in coagulation
parameters such as PT, PTT, or AT. In this study, a 15-days
treatment of intramuscular mesoglycan in patients recover-
ing from a cerebral ischemic episode produces signiﬁcantInternational Journal of Vascular Medicine 3
Table 1: Mesoglycan in ischemic stroke. Clinical studies.
Author Study design Pathology Patients (n) Doses/route Results
Oreﬁce [12] Prospective Stroke
(1–3 mo before)
30 Mesoglycan 50mg twice daily
orally for 3 months
Mesoglycan: safe and eﬀective in
reducing FBR without interfering
with other coagulative
parameters
Oreﬁce [11] Randomized
Controlled
Stroke
(2-3 mo before)
46
Mesoglycan 50mg twice daily
orally versus Ticlopidine 250mg
twice daily, for 2 months
Mesoglycan and ticlopidine: both
safe and eﬀective in reducing
FBR without interfering with
other coagulative parameters
Vecchio [13] Prospective Stroke
(within 2 mo)
20 Mesoglycan 30mg twice daily
intramuscular, for 15 days
Mesoglycan: signiﬁcant
reduction in FBR, cholesterol,
triglycerides, improved
erythrocyte ﬁlterability without
interfering with other
coagulative parameters
Mansi [14] Prospective TIA or stroke
(within 3 mo)
30 Mesoglycan 50mg twice daily
orally
Mesoglycan decreases neurologic
deﬁcits
Forconi [15] Multicenter
clinical trial
History of stroke,
TIA, RIND or
minor stroke
1,398
Mesoglycan 30mg twice daily
i.m., then 100mg daily orally,
versus ASA 300mg daily
No diﬀerences. ASA: higher
incidence of side eﬀects
changes in FBR and lipid plasma levels with no apparent
anticoagulant eﬀect [13]. The results of the present study
further support the concept that mesoglycan reduces plasma
FBR levels without altering coagulative parameters.
The mesoglycan eﬃcacy has also been evaluated in
chronic cerebrovascular disease, in a study [14]c o n d u c t e d
on a group of 30 patients (19 males, 11 females; mean-aged
± SD = 63.6 ± 8.7), with a history of transient ischemic
attacks (TIA) (30%) or ischemic strokes (70%) within the
3 months before the treatment. The patients were treated
with mesoglycan (50mg, twice a day) over 3 months. The
eﬃcacy of the drug in chronic treatment of cerebrovascular
disease was evaluated at basal time and after 30, 60, and
90 days by clinical examination using neurological and
neuropsychological rating scales. An improvement in mnesic
performances, mood, and autonomy in daily living activity
and a reduction in emotional lability was demonstrated by
the decrease of the rating scale mean scores. Instability at
Rombergtest,primitivereﬂexes,andweaknesswerethemost
often reversible neurological signs. This could be ascribed
to the eﬀect of the drug on hemoreological conditions
[14].
Recently, it has been showed that heparan sulphate pro-
teoglycans are the main antigenic components of cholinergic
synaptic vesicles, and may help to maintain the vesicles
membrane integrity during multiple cycles of secretion and
endocytosis [14].
Interestingly, Forconi et al. [15] compared the eﬃcacy
and tolerability of mesoglycan and acetylsalicylic acid (ASA)
in the prevention of vascular events after cerebral ischemic
events in a large multicenter clinical trial. In 48 Italian
clinical centers, 1,398 patients with a history of athero-
thrombotic stroke one or more episodes of TIA, reversible
ischemic neurological deﬁcit (RIND), or minor stroke with
the last episode occurring 14–90 days before admission were
randomized to mesoglycan 30mg i.m. twice daily for two
weeks, then 100mg/day orally (n = 701) or ASA 300mg
once daily (n = 697) [15]. Primary outcome events were
considered: reversible ischemic neurologic deﬁcits, stroke,
acute MI, or vascular death. At the end of followup period
(median duration 18 months), the number of primary
outcome events observed in the two treatment groups was
similar(125intheASAgroup,129inthemesoglycangroup);
major stroke was observed in 26 patients of the ASA group
and in 26 patients of the mesoglycan group; and deaths
from vascular causes were 37 and 32, respectively. Log-rank
statistics failed to evidence signiﬁcant diﬀerences between
treatment groups. On the other hand, a signiﬁcantly (P
< .01) higher incidence of side eﬀects was reported in the
ASA group [15].
These data, and particularly the absence of side eﬀects,
suggest that mesoglycan can be safely used in the manage-
ment of ischemic stroke in patients treated with standard
antiplatelet regimens, and additional and larger studies are
required to conﬁrm this hypothesis.
2.2.2. Peripheral Obstructive Arterial Disease [18–20]
(Table 2). Andreozzi et al. [18] evaluated the use of
mesoglycan in patients with peripheral obstructive arterial
disease (POAD). Ten patients with PAOD in stages I and II
according to Leriche-Fontaine were treated with mesoglycan
sulfate (60mg daily for twenty days) to evaluate the eﬀects of
the drug on the elastic modulus of the arterial wall. The wall
elasticity was deduced from some Doppler velocitographic
indices: arterial dynamics index (ADI), resistance index
(RI), perfusion pressure index (PPI), and tibial distensibility4 International Journal of Vascular Medicine
Table 2: Mesoglycan in peripheral obstructive arterial disease (POAD). Clinical studies.
Author Study design Pathology Patients (n) Doses/route Results
Andreozzi [18]Prospective POAD in stages
I-II Fontaine 10
Mesoglycan 60mg daily
for 20 days
Mesoglycan: safe and eﬀective in
improving the wall response to
vasodilator stimulus
Raso [19] Prospective POAD stage IIb
Fontaine 36
Mesoglycan 60mg daily
endovenous for 10 days then
100mg daily orally for 20 days,
repeated for two months then
oral mesoglycan for 12 months
Mesoglycan: signiﬁcant
improvement of symptoms and
signs in all patients but one
Nenci [20]
Randomized,
double-blinded
PAOD stage II
Fontaine 242
Mesoglycan 30mg daily i.m. for
3 weeks then 100mg daily orally
for two weeks, versus matching
placebo All patients receive ASA
Mesoglycan: signiﬁcant clinical
improvement versus placebo.
Signiﬁcant improvement in
quality of life scores.
index (TDI) from the analysis of systolic, protodiastolic,
and end-diastolic velocity variations and from computerized
analysis of the Doppler sound spectrum [18]. The treatment
with mesoglycan sulfate induced: (1) a reduction of mean
RI and PPI, which expresses a reduction of the peripheral
resistance on the arteriolo-capillary side and, thus, a better
endothelial function; (2) a reduction in the worsening of
the mean percent variations of the systolic window induced
by ischemia, which is a sign of a more homogeneous ﬂow
of the blood particles inside the vessel and of a better wall
responsiveness; and (3) an improvement of the wall response
to the vasodilator stimulus [18]. These results, obtained
in patients in a very early stage, should be ascribed to
the improvement of arteriolar reactivity mediated via the
improvement of the elastic modulus.
This study suggested a role of mesoglycan in the therapy
of arterial diseases, primarily in the treatment of the initial
stages of atherosclerotic, hypertensive, or diabetic arterial
diseases, wherein reduced elasticity of arterial wall is one of
the earliest functional impairments [18].
Nakashima et al. [21] described 2 patients with chronic
arterial occlusion in whom the intravenous (IV) adminis-
tration of mesoglycan was markedly eﬀective. One patient
suﬀered from thromboembolic episodes of the left hand,
due to a mural thrombus formed in an aortic aneurysm,
and the other had peripheral circulatory impairment related
to a collagen disease (periarteritis nodosa cutanea). In
these patients, the oral administration of anticoagulants
and antiplatelet agents in combination with IV infusion
of prostaglandin E1 (PGE1) was not adequately eﬀective.
However, the addition of IV injection of mesoglycan (30mg
twice daily) resulted in a marked improvement in the
signs and symptoms of both patients [21], suggesting that
mesoglycan may be useful for the treatment of chronic
arterial occlusion when combined with antithrombotic and
vasodilator drugs.
GAG administered IV seem to exert an anticoagulant
eﬀects by: inhibiting activated factor X (Xa), activating
ﬁbrinolytic agents, and inhibiting platelet aggregation [21,
22].
Theeﬀectofmesoglycanwasinvestigatedinpatientswith
acute episodes of relative lower limb ischemia (Stage IIb
according to Leriche-Fontaine classiﬁcation) [19]. Mesogly-
can was administered according to the following schedule:
a 10-days period of intravenous mesoglycan (90mg/day),
given in day-hospital regimen, followed by a 20-days period
of oral mesoglycan (100mg/day). The treatment schedule
was repeated for two months and then patient continued
with oral mesoglycan. Thirty-six patients were followed
for a mean period of 12 months. From February 1995,
thirty-six patients, 24 males and 12 females, aged between
45 and 83 years (mean ± SD: 69.8 ± 7.5) with acute
relative lower limb ischemia were enrolled. At baseline, the
diagnosis was Fontaine’s IIb stage (walking distance < or
= 200m) in all patients, 17 patients presenting walking
distance < 100m. After 3 and 6 months of mesoglycan
treatment a signiﬁcant improvement of symptoms and signs
was observed in all patients but one. At the end of the 6-
months period, 29 patients (81% of the study population)
became to a Fontaine’s IIa degree, with a signiﬁcant increase
in walking distance (in 70% three times their basal value)
and improvement of symptoms and recovery time. After
treatment, Winsor Index was not signiﬁcantly modiﬁed.
Similar results were obtained after 12 months of followup.
During the study period only one patient included in the
trialneededsurgicalrevascularisation.Theadministrationof
mesoglycan was well tolerated, with only minor complaints
in two patients (one case of headache and one of diarrhea).
During the intravenous administration of mesoglycan most
patients (81%) presented values of aPTT 2.0 times con-
trol, which returned to normal values at the end of the
administration. This results showed that in patients with
acute episodes of relative lower limb ischemia, mesoglycan
(administered according to the described protocol) was an
eﬀective and safe agent able to improve symptoms (walking
distance, pain, and leg appearance) and to possibly delay the
need of surgical interventions.
Nenci et al. [20] studied the eﬀect of treatment with
mesoglycan on the walking capacity of patients with stage
II peripheral arterial disease. Nondiabetic outpatients withInternational Journal of Vascular Medicine 5
intermittent claudication, duplex ultrasound evidence of
peripheral atherosclerosis, ankle/arm index <0.80, systolic
ankle pressure >50mmHg, and absolute walking distances
(AWD) between 100 and 300m (standardized treadmill
test) were eligible. After a 5 week run-in on single-blind
placebo, 242 patients were randomized to double-blind
treatment with mesoglycan, 30mg/day intramuscularly for
3 weeks followed by 100mg daily orally, for 20 weeks, or
matching placebo. All patients received low-doses aspirin
and lifestyle instructions. Clinical response was deﬁned as
an AWD increase at Week 23 > 50% over baseline. Health-
related quality of life and ischemic events were assessed as
secondary eﬃcacy variables [22]. Patients achieving clinical
response were 59/118 with mesoglycan (50%) and 31/119
with placebo (26.1%; P < .001). Geometric mean AWD
increased from 192m to 298m with mesoglycan, and from
192m to 238m with placebo (P < .001). Pain-free walking
distance showed a nonsigniﬁcant increase with mesoglycan
(P = .057). Changes in quality of life scores were in favor
of mesoglycan. The rate of ischemic events was 1/120 on
mesoglycanand6/122onplacebo(P = .053).Therateofnon
ischemicadverseeventsleadingtotreatmentdiscontinuation
was 7/120 and 4/122, respectively. In conclusion, treatment
of intermittent claudication with mesoglycan increased
the proportion of patients achieving a clinical interesting
(>50%) improvement in maximal walking capacity. The
treatment was well-tolerated, even in conjunction with
antiplatelet therapy, and was unlikely to have any adverse
inﬂuence on the course of the underling atherothrombotic
disease.
In terms of beneﬁt/risk ratio, therefore, mesoglycan
compares favorably with pharmacological therapies for
PAOD and represents an attractive option for the medical
management claudication [19].
2.3. Venous Disease (Table 3). Some studies suggest the
eﬃcacy of mesoglycan and GAG in venous pathology too
[23–30].
Chronic venous insuﬃciency (CVI), the postthrombotic
syndrome (PTS), and ulceration represent an important
medical problem because of its prevalence (0.3% of the
Western population) and healthcare costs [23, 27].
Arosio et al. [23] found a faster and more frequent ulcer
healing in patients with chronic venous ulcers treated with
mesoglycan in addition to established venous ulcer therapy
(limb compression and topical wound care). One hundred
and eighty-three patients were randomized to the treatment
with mesoglycan (30mg intramuscularly for three weeks
followed by 100mg/day orally) (n = 92) or placebo (n =
91) and the treatment was continued until complete ulcer
healing or for 24 ± 1w e e k s[ 23]. The estimated time to heal
75% of the patients was 90 days on mesoglycan versus 136
on placebo, while the cumulative rate of healing by the end
of observation was 97% versus 82%, respectively, [23]. The
diﬀerence between treatments was statistically signiﬁcant (P
< .05).
The mechanism by which ulcer healing was promoted
by treatment with mesoglycan is not clear. Mesoglycan
may counteract putative mechanism for venous ulceration
through inhibition of neutrophil adhesion and activation
[28], prevention of endothelial barrier function, prevention
ofﬁbrinformation,andenhancementofﬁbrinolysis[23,28].
An alternative explanation is suggested by recent reports
highlighting the role of physiological dermatan and heparin
sulphate in wound healing processes [29], including cuta-
neous wound repair [30].
Andreozzi [24] et al. demonstrated an eﬀectiveness
of mesoglycan treatment in preventing thrombotic recur-
rence in patients with previous DVT, and improvement
in disability, pain, and oedema in patients with CVI in a
retrospective analysis. The clinical data have been selected
from the outpatient database of the Chair of Angiology
of the University of Catania (from 1988 to 1997) through
a cross survey between the prescription commercial name
of mesoglycan and the key words: varicose veins, DVT,
CVI, postthrombotic syndrome (PTS), venous thrombosis,
and venous ulcer [24]. Patients have been selected on the
basis of data relative to principal diagnosis, clinical history,
clinical and instrumental objective phlebological picture,
dosage and duration of treatment, and follow-up visits in the
ﬁrst three years following the ﬁrst observation: Group 1:56
patients with ﬁrst episode DVT; Group 2:27 patients with
recurrent DVT; Group 3:182 patients with CVI (107 with
primitive CVI and 75 with secondary CVI). DVT patients
were evaluated for recurrence prevalence during the follow
up period (6, 12, 18, 24, 30, and 36 months). In group 2
the recurrence prevalence in the normal follow up period
was evaluated and, in addition, the clinical chronology of the
recurrence previous to observation was drawn, in order to
ﬁnd out the recurrence prevalence of the thrombotic episode
precedingthestudy.CVIpatientswereclassiﬁedaccordingto
CEAP criteria and the eﬃcacy of the treatment was assessed
according to the changes in the scores of venous dysfunction
(disability score, pain, oedema, skin color change, and
cutaneous ulcer). The mean dose of mesoglycan was 50mg
twice daily. The results obtained in groups 1 and 2 showed
that mesoglycan was eﬀective in preventing thrombotic
recurrence in patients with previous DVT. The recurrence
prevalence in patients with DVT at ﬁrst episode was lower
than the prevalence reported by the literature data (17.5%
within 2 years and 24.6% within 5 years). The positive trend
was also conﬁrmed in the recurrence DVT group, although
with a major prevalence (18.51%) due to higher thrombotic
risk. Mesoglycan was also eﬀective in CVI patients, with
a signiﬁcant improvement of disability, pain, oedema, and
quality of life [24]. This retrospective analysis outlines an
interesting therapeutic proﬁle for mesoglycan in chronic
venous disorders, and studies are needed in this issue.
The asymmetrical lower extremity swelling is known as
“mechanical oedema” (MO) and may interest ankle, calf,
and knee. The treatment of MO needs a multidisciplinary
approach which includes speciﬁc training for muscular
pump and pharmacological treatment focused to correct
venous endothelium alterations [25, 31–33].
The study of Viliani et al. [25] evaluated the clinical
eﬃcacy of mesoglycan 50mg twice a day in patients aﬀected
by MO. Forty-four patients with MO were randomized
in two treatment groups: (1) speciﬁc physiotherapy (Fkt)6 International Journal of Vascular Medicine
Table 3: Mesoglycan and venous disease.
Author Study design Pathology Patients (n) Doses/route Results
Arosio [23] Randomized Chronic venous
ulcers
183
Mesoglycan 30mg daily i.m. for
3 weeks then 100 mg daily orally,
versus placebo, for 24 ± 1w e e k s
Mesoglycan: signiﬁcant
diﬀerence in the rate of ulcer
healing versus placebo
Andreozzi [24] Retrospective
analysis
Patients with
previous DVT
36 Mesoglycan 50mg twice daily
orally
Mesoglycan: eﬀective in
preventing thrombotic
recurrences
Viliani [25] Randomized Mechanical
oedema (MO)
44 FKT+Mesoglycan 30mg twice
daily orally versus FKT alone
Mesoglycan: signiﬁcant clinical
improvement in objective and
subjective parameters
Prandoni [26] Randomized
DVT
venographically
proved
90
Heparin and then oral
anticoagulation (12 weeks), then
mesoglycan 72mg daily orally
versus placebo, for 1 year
Recurrences of DVT and/or PE
less frequent with mesoglycan
versus placebo (nonsigniﬁcant
diﬀerence)
alone or (2) Fkt plus mesoglycan 50mg twice a day, per
os. The patients were evaluated before treatment (T0) and
after 1 month of treatment (T1), measuring ankle joint
range of motion (degrees), calf circumference, and malleolar
circumference (cm), pain Borg CR10 scale and adapted lym-
phoedema Weiss Scale. At ﬁnal evaluation of the objective
and subjective parameters, the mesoglycan eﬀect combined
to the Fkt provided statistical diﬀerences on nearly all the
parameters in comparison with the patients randomized to
fkt alone [25]. The present study suggest that mesolgycan
treatment (50mg per os twice a day) can improve the
recovery of MO, and it is well tolerated by the patients.
Speciﬁc physiotherapy remains the ﬁrst treatment for the
recoveryofbothmuscularpumpandcorrectwalking,butthe
optimal treatment of MO seems to be a synergic approach,
including both pharmacological and mobilization programs.
Prandoni et al. studied ninety consecutive patients
aﬀected by venographically proven DVT of the lower limbs,
were given full-dose heparin followed by oral anticoagulants
for 12 weeks and then selected randomly to receive, for
one year, either mesoglycan (72mg/day orally) or placebo
with a double-blind protocol [26]. All patients wore elastic
graduated compression stockings and were prospectively
followed for a period ranging from 5 to 48 months. In each
scheduled examination programmed every three months
for one year and then twice per year, an accurate clinical
evaluation was performed and a predetermined objective
score was applied. Furthermore, impedance plethysmogra-
phy and Doppler ultrasound tests were executed serially
to assess the persistence of venous obstruction and/or the
development of valve incompetence. After a mean follow-up
of 3 years, 80% of the patients were totally asymptomatic,
and severe postthrombotic sequelae (ulcer and/or oedema)
were recorded in only 6 patients (6.6%). The authors
failed to identify any correlation between post-thrombotic
sequelae and persistence of venous obstruction (as shown
by impedance plethysmography) or development of valve
incompetence (as shown by Doppler ultrasound test). The
behaviour of patients treated with mesoglycan did not
diﬀer from that of patients treated with placebo. However,
objectively documented recurrences of DVT and/or pul-
monary embolism were less frequent in patients treated with
mesoglycan (6.6 versus 11.1%, nonsigniﬁcant diﬀerence),
andtheonlytwodeathsattributabletopulmonaryembolism
occurred among the patients treated with placebo [26].
The other GAG preparation, sulodexide, that is adminis-
tered intramuscularly or orally has shown to increase venous
ulcer healing in a placebo-controlled trial of 235 patients
without an apparent increase in side eﬀects [34–36].
3. Conclusions and Perspectives
Vascular GAG are essential component of the endothelium
and vessel wall and are involved in several biologic functions.
Mesoglycan is a natural GAG preparation, with antithrom-
boticandpro-ﬁbrinolyticactivities,whichhasbeenshownto
be clinically eﬀective in a number of vascular atherosclerotic
disorders with thrombotic risk. GAG have several actions
on the ﬁbrinolytic system, on vascular endothelium, and
on rheologic parameters. Mesoglycan has proven eﬃcacy in
reducing plasma FBR levels and the risk of recurrences in
patients with cerebral arterial disease, with a good safety
proﬁle. These antithrombotic and pro-ﬁbrinolytic activities,
although not indicated in the treatment of acute arterial
or venous thrombosis due to the low anticoagulant eﬀect,
suggest that mesoglycan may be useful in the management
of vascular diseases, when combined with antithrombotics
in the case of disease of cerebral vasculature, and with
antithrombotics and vasodilator drugs in the case of chronic
peripheral arterial disease. The protective eﬀect of meso-
glycan in patients with venous thrombosis or PTS and the
absence of side eﬀects support the use of GAG in patients
with CVI and persistent venous ulcers, in association with
compression therapy (zinc bandages, multiple layer ban-
dages,etc.),elasticcompressionstockings,andlocalcare,and
in the prevention of recurrences in patients with previous
DVT, following the standard course of oral anticoagulation
treatment.International Journal of Vascular Medicine 7
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